Cardiac Changes in Early Parkinson's Disease: a Follow Up Study

PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

December 30, 2019

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2025

Conditions
REM Sleep Behavior DisorderPre-motor Parkinson DiseaseSymptomatic Parkinson Disease
Interventions
DRUG

Carvedilol

Primary procedures in this study are MIBG scan, DAT scan, NM-MRI, and carvedilol titration. Subjects will return for research visits and imaging every six months for three years. The investigators hypothesize that the rate of decline in DAT scan123I-Ioflupane uptake will be slower in subjects who have received the adrenergic blocker carvedilol, resulting in a decreased clinical phenoconversion rate to parkinsonism.

Trial Locations (1)

90046

Michele L Lima Gregorio, Los Angeles

All Listed Sponsors
lead

Cedars-Sinai Medical Center

OTHER